Sonova stock gains as Bank of America lifts price target on strong hearing-aid demand

Published on 09/19/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sonova stock is trading firmly after Bank of America Global Research raised its price target to 280.00 francs on September 18, 2026, citing robust hearing-aid demand. The shares recently closed at 235.00 francs on the SIX Swiss Exchange, near the 52-week high of 248.00 francs.

A photorealistic audiology examination scene showing a patient wearing large professional audiometry headphones seated in a sound booth, while an audiologist in a white coat operates a clinical control panel with an audiogram chart displayed on a monitor — Sonova CH0012549785: Fotorealistische Audiologie-Untersuchung mit Patient, Kopfhörern und Audiogramm-Bildschirm in moderner Klinik, Illustration mit AI erstellt.

Sonova Holding AG stock (ISIN CH0012549785) is trading firmly after Bank of America Global Research raised its price target to 280.00 francs from 225.00 francs, with the shares having closed at 235.00 francs on the SIX Swiss Exchange on September 17, 2026 and remaining within sight of their 52-week high of 248.00 francs reached on August 24, 2026.

Bank of America lifts Sonova price target

According to Finimize on September 18, 2026, Bank of America Global Research raised its price objective for Sonova to 280.00 francs from 225.00 francs after observing that demand for hearing aids is running at the top end of expectations so far this year, reinforcing confidence in the company’s growth trajectory.

The new Bank of America target of 280.00 francs stands clearly above the average analyst target price of about 233.84 francs and implies an upside of roughly 19.1 percent compared with Sonova’s most recent closing price of 235.00 francs on September 17, 2026, underscoring the bank’s more optimistic stance than the broader market consensus.

Stock performance and valuation context

Per Swiss Exchange data summarized in recent market overviews, Sonova stock closed at 235.00 francs on the SIX Swiss Exchange on September 17, 2026, marking a gain of 1.12 percent over the prior close and reflecting a year-to-date performance of 2.44 percent as of September 18, 2026, which positions the shares as a moderate outperformer in the Swiss Performance Index.

Intraday trading on September 18, 2026 saw Sonova shares fluctuate between 233.20 francs and 234.60 francs, with the stock down 0.2 percent at 234.60 francs in the afternoon session, while the broader Swiss Performance Index stood at 19,572 points, according to data from Finanzen.ch, highlighting that the stock can be volatile around analyst-driven news.

The 52-week high of 248.00 francs reached on August 24, 2026 stands 5.71 percent above the level of 234.60 francs cited for the afternoon of September 18, 2026, showing that despite the recent pullback the shares remain relatively close to their yearly peak and that Bank of America’s 280.00-franc target would require the stock to move around 12.9 percent beyond that 52-week high if achieved.

Analyst expectations and demand outlook

As Finimize reports, Bank of America’s analysts see the global hearing-aid market tracking the upper end of Sonova management’s 2 to 4 percent growth view for the current fiscal year so far, which strengthens their case for faster sales and profit growth at the group as patient volumes and replacement demand remain robust.

Bank of America now forecasts 7.2 percent constant-currency sales growth for Sonova in fiscal 2027, a rate it says is about 0.8 percentage points above the broader analyst consensus compiled across the market, implying that the bank expects the company to expand revenue meaningfully faster than peers and the average expectation if its assumptions about demand hold.

The research note cited by Finimize also indicates that Bank of America expects Sonova’s results to be unusually weighted toward the first half of fiscal 2027, which suggests that investors should pay close attention to upcoming interim figures because they may carry a disproportionate share of the year’s earnings and could influence sentiment strongly.

Risk considerations for investors

While the Bank of America upgrade is a positive catalyst, the trading data from Finanzen.ch show that Sonova’s share price can move noticeably within a single session, with an intraday low of 233.20 francs and a high of 234.60 francs on September 18, 2026, reflecting sensitivity to both sector sentiment and company-specific news in a relatively concentrated market segment.

For investors, a key risk is that hearing-aid demand could fall back toward the lower end of the 2 to 4 percent growth corridor or below if economic conditions weaken or reimbursement frameworks tighten, which would challenge Bank of America’s 7.2 percent sales growth assumption for fiscal 2027 and could prompt downward revisions to both earnings forecasts and the 280.00-franc price target.

Sonova stock and current valuation

As of the last completed trading day, Sonova stock’s closing price of 235.00 francs on the SIX Swiss Exchange on September 17, 2026 places it between the average target of around 233.84 francs and Bank of America’s raised objective of 280.00 francs, indicating that the market price currently aligns closely with consensus but still embeds potential upside if the more bullish scenario materializes.